(19)
(11) EP 3 635 129 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
15.09.2021 Bulletin 2021/37

(45) Mention of the grant of the patent:
28.07.2021 Bulletin 2021/30

(21) Application number: 18727021.0

(22) Date of filing: 01.06.2018
(51) International Patent Classification (IPC): 
C12Q 1/6886(2018.01)
(52) Cooperative Patent Classification (CPC):
C12Q 1/6886; C12Q 2600/156
(86) International application number:
PCT/EP2018/064479
(87) International publication number:
WO 2018/224406 (13.12.2018 Gazette 2018/50)

(54)

METHODS FOR CHARACTERIZING LOSS OF ANTIGEN PRESENTATION

VERFAHREN ZUR CHARAKTERISIERUNG DES VERLUSTES VON ANTIGENPRÄSENTATION

PROCÉDÉS DE CARACTÉRISATION DE PERTE DE PRÉSENTATION DE L'ANTIGÈNE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 09.06.2017 WO PCT/EP2017/064112

(43) Date of publication of application:
15.04.2020 Bulletin 2020/16

(60) Divisional application:
21186973.0

(73) Proprietors:
  • BioNTech SE
    55131 Mainz (DE)
  • TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH
    55131 Mainz (DE)

(72) Inventors:
  • SAHIN, Ugur
    55131 Mainz (DE)
  • SUCHAN, Martin
    55129 Mainz (DE)
  • SCHRÖRS, Barbara
    55124 Mainz (DE)
  • LÖWER, Martin
    55131 Mainz (DE)
  • OEHM, Petra
    55131 Mainz (DE)

(74) Representative: Schnappauf, Georg 
ZSP Patentanwälte PartG mbB Hansastraße 32
80686 München
80686 München (DE)


(56) References cited: : 
   
  • D'URSO C M ET AL: "LACK OF HLA CLASS I ANTIGEN EXPRESSION BY CULTURED MELANOMA CELLS FO-1 DUE TO A DEFECT IN B2M GENE EXPRESSION", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 87, 1 January 1991 (1991-01-01), pages 284-292, XP002051964, ISSN: 0021-9738, DOI: 10.1172/JCI114984
  • ANNETTE PASCHEN ET AL: "Complete loss of HLA class I antigen expression on melanoma cells: A result of successive mutational events : HLA Class I Antigen Loss", INTERNATIONAL JOURNAL OF CANCER, vol. 103, no. 6, 12 December 2002 (2002-12-12), pages 759-767, XP055399467, US ISSN: 0020-7136, DOI: 10.1002/ijc.10906
  • A. PASCHEN ET AL: "The Coincidence of Chromosome 15 Aberrations and 2-Microglobulin Gene Mutations Is Causative for the Total Loss of Human Leukocyte Antigen Class I Expression in Melanoma", CLINICAL CANCER RESEARCH, vol. 12, no. 11, 1 June 2006 (2006-06-01), pages 3297-3305, XP055399450, US ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-05-2174
  • MONICA BERNAL ET AL: "Implication of the Î2-microglobulin gene in the generation of tumor escape phenotypes", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 61, no. 9, 26 July 2012 (2012-07-26), pages 1359-1371, XP035103281, ISSN: 1432-0851, DOI: 10.1007/S00262-012-1321-6
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).